Previous studies have reported that MBD3 has the highest cancer mutation rate in pancreatic cancer, and some research has shown that MBD3 has an anti-tumour effect in pancreatic cancer; specifically, it can inhibit the EMT of pancreatic cancer cells through TGF-β/smad signaling pathway [11]. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.